BioStock: The temperature of Cereno Scientific after major news

Cereno Scientific has recently announced the selection of a rare disease, idiopathic pulmonary fibrosis, as the target indication for its second drug candidate, CS014. Along with the new data for its lead candidate, CS1, this marks a clear shift in strategy and focus: rare diseases that today leave patients without effective treatment options. CEO Sten R. Sörensen visited BioStocks studio to talk more about this.

Watch the interview with CEO Sten R. Sörensen at biostock.se:

https://www.biostock.se/en/2024/10/the-temperature-of-cereno-scientific-after-major-news/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/